Abstract | BACKGROUND: METHODS: A total of 59 nonshock patients with STEMI admitted <12 hours to remote hospitals with anticipated delay to PPCI of <90 minutes were randomly assigned to 2 study groups: 27 patients received abciximab before transfer to catheterization laboratory (Early group), and 32 patients received abciximab immediately before PPCI (Late group). RESULTS: Angiography revealed more frequent infarct-related artery patency in the Early group than in the Late group (TIMI 2 + 3: 48% vs 20%, P = .04). Better ST-segment resolution of >50% 60 minutes after PPCI was found in Early group than in the Late group (84% vs 56.7%, P = .04). The area under the curve for creatine kinase-MB indicated a significantly greater extent of myocardial injury in the Late group versus the Early group (8324 +/- 4185 vs 5938 +/- 3949 U/L . h, P = .04). There was a significant difference in the 30-day left ventricular end-systolic volume index (P = .02) and end-diastolic volume index (P = .05) in the echocardiography favoring the Early group. CONCLUSIONS: Early abciximab administration before transfer for PPCI in patients with first anterior wall STEMI results in more frequent infarct-related artery patency before PPCI, better myocardial tissue perfusion after PPCI, with lower enzymatic infarct size and lower degree of left ventricular remodeling during 30-day follow-up.
|
Authors | Tomasz Rakowski, Jaroslaw Zalewski, Jacek Legutko, Stanislaw Bartus, Lukasz Rzeszutko, Artur Dziewierz, Danuta Sorysz, Leszek Bryniarski, Krzysztof Zmudka, Grzegorz L Kaluza, Jacek S Dubiel, Dariusz Dudek |
Journal | American heart journal
(Am Heart J)
Vol. 153
Issue 3
Pg. 360-5
(Mar 2007)
ISSN: 1097-6744 [Electronic] United States |
PMID | 17307412
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Abciximab
|
Topics |
- Abciximab
- Aged
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal
(administration & dosage)
- Coronary Angiography
- Female
- Humans
- Immunoglobulin Fab Fragments
(administration & dosage)
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(diagnostic imaging, physiopathology, therapy)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Stroke Volume
- Time Factors
- Vascular Patency
(drug effects)
- Ventricular Function, Left
(drug effects)
|